Scotiabank Notes Bristol-Myers Squibb Company (BMY) as Appealing Investment in 2026
Scotiabank has raised its price target for Bristol-Myers Squibb (BMY) to $60, citing the company’s low valuation and a catalyst-rich year ahead in 2026, driven by advancements in its oncology and immunology pipeline, delayed patent cliffs, and strong financial positioning that positions it for potential outperformance in the pharmaceutical sector. Bristol-Myers Squibb stands out in … Read more